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MaBACKGROUND Sustained right ventricular (RV) apical pacing may lead to deterioration in ventricular function and an
increased risk of heart failure, especially in patients with pre-existing systolic dysfunction. The BLOCK HF (Biventricular
Versus Right Ventricular Pacing in Heart Failure Patients With Atrioventricular Block) trial demonstrated that
biventricular-paced patients had a reduced incidence of a composite endpoint of death, heart failure–related urgent care,
and adverse left ventricular remodeling.
OBJECTIVES In a pre-speciﬁed analysis, this study examined clinical outcomes, including clinical composite score,
quality of life (QOL), and change in New York Heart Association (NYHA) functional classiﬁcation.
METHODS The BLOCK HF trial randomized patients with atrioventricular block, NYHA symptom class I to III heart
failure, and left ventricular ejection fraction#50% to biventricular or RV pacing. NYHA functional classiﬁcation, QOL, and
clinical composite score were assessed at 6, 12, 18, and 24 months. Bayesian statistical methods were used, with the
pre-speciﬁed metric of beneﬁt being a posterior probability $0.95.
RESULTS Patients with biventricular pacing showed greater improvement in NYHA functional class at 12 months, with
19% improved, 61% unchanged, and 17% worsened, compared with 12%/62%/23% in the RV arm. QOL was improved
through 12 months. At 6 months, clinical composite score was improved/unchanged/worsened in 53%/24%/24% in the
biventricular arm compared with 39%/33%/28% in the RV arm. This improvement in clinical composite score was
sustained through 24 months.
CONCLUSIONS For patients with atrioventricular block and systolic dysfunction, biventricular pacing not only reduces
the risk of mortality/morbidity, but also leads to better clinical outcomes, including improved QOL and heart failure
status, compared with RV pacing. (Biventricular Versus Right Ventricular Pacing in Heart Failure Patients With Atrio-
ventricular Block [BLOCK HF]; NCT00267098) (J Am Coll Cardiol 2016;67:2148–57)
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AB BR E V I A T I O N S
AND ACRONYM S
CRT = cardiac
resynchronization therapy
CRT-D = cardiac
resynchronization therapy
deﬁbrillator
CRT-P = cardiac
resynchronization therapy
pacemaker
LOCF = last observation
carried forward
LVEF = left ventricular
ejection fraction
NYHA = New York Heart
Association
PP = posterior probability
QOL = quality of life
RV = right ventricular
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2149C linical trials have shown that long-term rightventricular (RV) pacing can lead to worseoutcomes compared with low-rate (backup)
ventricular pacing in patients with pacemakers and
implantable cardioverter deﬁbrillators who have
intact atrioventricular conduction (1,2). For such pa-
tients, algorithms that minimize ventricular pacing
yet provide ventricular rate support when needed
have become widely adopted (3). However, patients
with atrioventricular block may require pacing all or
most of the time. The BLOCK HF (Biventricular
Versus Right Ventricular Pacing in Heart Failure Pa-
tients With Atrioventricular Block) study (4) tested
the hypothesis that, in patients with atrioventricular
block, left ventricular ejection fraction (LVEF)
#50%, and New York Heart Association (NYHA)
functional class I to III symptoms, biventricular pac-
ing would be superior to RV pacing with respect to a
combined endpoint of death, heart failure–related ur-
gent care, or adverse left ventricular remodeling as
manifested by a $15% increase in left ventricular end
systolic volume index. The trial showed a 26% reduc-
tion in the combined endpoint in favor of biventricu-
lar pacing (5). In addition to morbidity and mortality,
clinical outcomes are also vitally important in patients
with atrioventricular block and left ventricular
dysfunction. In a pre-speciﬁed analysis, our speciﬁc
aim was to examine clinical outcomes, including qual-
ity of life (QOL), NYHA functional classiﬁcation, and
clinical composite score in patients in BLOCK HF.SEE PAGE 2158METHODS
Enrollment criteria for the prospective, multicenter,
randomized, double-blind, controlled BLOCK HF trial
have been published previously (4). All patients had a
standard class I or IIa indication for permanent pacing
due to atrioventricular block, NYHA functional class I
to III systolic heart failure, and LVEF #50%. Patients
with permanent atrial arrhythmias who had intrinsic
atrioventricular block or atrioventricular block due to
atrioventricular node ablation, as well as patients
meeting class I indications for implantable cardiac
deﬁbrillators, were enrolled. All subjects received
either a cardiac resynchronization therapy (CRT)
pacemaker (CRT-P) or deﬁbrillator (CRT-D) and
received RV pacing for 30 to 60 days while heart
failure medical therapy was optimized. Subjects were
subsequently randomly assigned in a 1:1 ratio to
receive biventricular (both RV and left ventricular
pacing outputs ON) or RV (RV pacing output ON,
left ventricular pacing output OFF) pacing, and
underwent an echocardiographic examination atrandomization and 6, 12, 18, and 24 months
post-randomization.
Pre-speciﬁed outcomes included the Packer
clinical composite score (6), QOL, and NYHA
functional class. The Packer clinical compos-
ite score classiﬁes each patient into 1 of 3
categories (improved, worsened, unchanged),
and is determined using clinical outcomes,
heart failure status, and patient symptoms.
Subjects are assigned a score of worsened if
they have died, experienced a heart failure
hospitalization, discontinued therapy due to
worsening heart failure, experienced wors-
ening symptoms as deﬁned by higher NYHA
functional classiﬁcation, or have developed
moderately or markedly worse symptoms
relative to baseline as determined by the
subject. In the absence of a score of worsened,
the subject receives a score of improved if
they have experienced improvement in NYHA func-
tional classiﬁcation relative to baseline or have had
moderately or markedly reduced symptoms as deter-
mined by the subject. A score of unchanged is assigned
if none of these criteria are met. QOL was measured
using the Minnesota Living With Heart Failure Ques-
tionnaire. Each endpoint was assessed at 6, 12, 18, and
24 months. Changes at follow-up were compared with
randomization.
STATISTICAL METHODS. An adaptive Bayesian study
design was used, including sample size re-estimation
that would halt enrollment once pre-speciﬁed criteria
for either futility or eventual success were met. There
were 2 interim analyses to curtail follow-up if there
was sufﬁcient evidence to conclude the primary
objective was met. The trial was designed to follow all
randomized subjects through at least 12 months of
follow-up unless the trial was halted at an interim
analysis.
Clinical endpoints at the 6-, 12-, 18-, and 24-month
visits were a subject’s clinical composite score, ab-
solute change in NYHA functional classiﬁcation from
randomization, and absolute change in QOL from
randomization. For the QOL and NYHA analyses, at
each time point, only subjects with paired data
(values at randomization and the time point of in-
terest) were included in the analysis. In the case of
the clinical composite score, the last observation
carried forward (LOCF) method was used, which did
not require a subject to complete a follow-up visit at
the time point of interest to be included in the cor-
responding analysis. However, to prevent artiﬁcial
extension of a subject’s status due to study closure,
subjects were excluded from the analysis at a given
time point if: 1) the subject had not died, experienced
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randomized therapy due to worsening heart failure;
and 2) did not complete a visit at that time point due
to the study being stopped before the subject having
the opportunity to complete the visit.
NYHA functional class change from randomization
was assigned a value from 3 to þ3 depending on how
many classes the subject worsened or improved at
that time point. For clinical composite score, the
scores coded worsened were assigned a value of 1,
unchanged, a value of 0, and improved, a value of þ1.
In the case of QOL, the difference between randomi-
zation and follow-up served as the endpoint. The
primary metrics of analysis were: 1) the posterior
distribution, which for an endpoint reﬂects the likely
set of values the endpoint can take based on pre-trial
assumptions and accumulated data; and 2) the 95%
credible interval, which is generated from the 2.5th
and 97.5th percentiles of the posterior distribution
and reﬂects the range of values the endpoint can take
with 95% probability. For each endpoint, the pre-
speciﬁed threshold for demonstrating biventricular
therapy superiority statistically was a posterior
probability (PP) of at least 0.95, which would indicate
that, on average, patients with biventricular therapy
had superior endpoint measures compared with pa-
tients with RV therapy.
A nonparametric method was used to compare
clinical composite score and changes in NYHA func-
tional class over time between randomization arms.
For each time point (e.g., 6 months), the endpoints
were ranked across randomization arms. Letting mBiV
and mRV denote the average rank in each arm, ﬂat
priors were assigned to these quantities, ensuring
the posterior means would be the respective
sample means (ӯBiV, ӯRV), and the posterior standard
deviations would be the sample standard errors
(sBiV/OnBiV, sRV/OnRV). The posterior distribution for
mBiV  mRV is N(ӯBiV  ӯRV, s2BiV/nBiV þ s2RV/nRV). Under
this distribution, if P(mBiV  mRV < 0) $0.95, it was
concluded that the difference between therapy
groups was important and patients with biventricular
pacing performed better at that time point than
patients with RV pacing.
In the analysis of QOL, for each time point, let XBiV
and XRV denote the (randomization  time point of
interest) change in QOL score of randomly selected
subjects from the biventricular pacing arm and RV
pacing arm, respectively. Then XBiV w N(mBiV, s2BiV)
and XRV w N(mRV, s2RV). The prior distributions for
mBiV and mRV were assumed to be N(0, 102), and the
prior distributions for 1/s2BiV and 1/s2RV were
assumed to be gamma (0.001, 0.001), which had a
mean of 1 and variance of 1,000. The marginalposterior distribution for mBiV  mRV was computed,
and if the PP denoting P (mBiV  mRV > 0jdata,
prior) $0.95, it was concluded that patients with
biventricular pacing saw greater improvement in QOL
at that time point than patients with RV pacing.
Sensitivity analyses were performed to account for
crossovers. For both NYHA functional class and QOL,
subjects who crossed over in their ﬁrst 24 months had
their most recent pre-crossover value substituted for
all post-crossover endpoint values (LOCF). Because
clinical composite score includes discontinuation of
therapy due to heart failure as a component, sensi-
tivity analyses were not necessary for this endpoint.
Poolability analyses were performed for each
endpoint to assess differences between device
groups. This was done by performing the analyses
previously discussed within each device group, then
determining the posterior distribution for the
CRT-P  CRT-D difference with respect to mBiV  mRV.
A 95% 2-sided credible interval for this difference was
generated, and if that interval contained 0 (reﬂecting
equivalence between the device groups), the data
were considered poolable across device groups.
RESULTS
A total of 918 patients were enrolled from December
2003 through November 2011 at 58 sites in the United
States and 2 sites in Canada. Of enrolled subjects, 691
were randomized, with 349 allocated to biventricular
pacing and 342 allocated to RV pacing (Figure 1).
Within device groups (CRT-P and CRT-D), demo-
graphics were comparable between arms at random-
ization (Table 1). Poolability analyses did not show
signiﬁcant differences between CRT-D and CRT-P
groups in the biventricular–RV comparison, and so
data were pooled across device groups for the main
analyses. Follow-up compliance across the 6-, 12-, 18-,
and 24-month visits was 94.7%, 94.2%, 92.7%, and
92.7%, respectively. Crossovers were more prevalent
in the RV arm than the biventricular arm (Figure 1).
There were 104 crossovers (86 in the RV arm, 18 in the
biventricular arm) that occurred post-randomization.
Among the biventricular-paced subjects, 11 cross-
overs were due to diaphragmatic stimulation. Four-
teen of the crossovers occurred within 24 months of
randomization. Among the 86 RV-paced subjects who
crossed over, 71 did so due to worsening heart failure,
whereas 7 were due to programming errors. Fifty-four
of the 86 subjects who crossed over to biventricular
pacing met a primary endpoint before crossover.
PACKER CLINICAL COMPOSITE SCORE. Biventricular
pacing was superior to RV pacing at all time points
(Table 2) (PP$ 0.99). At 6 months, 53% of biventricular
FIGURE 1 Consort Diagram
Enrollment
Allocation
Follow-up
Crossovers
918 Assessed for eligibility
691 Randomized 1:1
227 Subjects not randomized:
95 for whom inclusion criteria not met
      prior to implant
14 subject withdrawals prior to implant
51 Unsuccessful implants
67 Implanted subjects not randomized
349 Allocated to BIV Pacing 342 Allocated to RV Pacing
349 Included in 6 Month CCS Analysis
345 Included in 12 Month CCS Analysis
325 Included in 18 Month CCS Analysis
308 Included in 24 Month CCS Analysis
342 Included in 6 Month CCS Analysis
341 Included in 12 Month CCS Analysis
323 Included in 18 Month CCS Analysis
314 Included in 24 Month CCS Analysis
331 Completed 6 Month Visit
312 Included in NYHA analysis
304 Included in QOL analysis
306 Completed 12 Month Visit
281 Included in NYHA analysis
274 Included in QOL analysis
269 Completed 18 Month Visit
242 Included in NYHA analysis
237 Included in QOL analysis
237 Completed 24 Month Visit
217 Included in NYHA analysis
214 Included in QOL analysis
319 Completed 6 Month Visit
293 Included in NYHA analysis
289 Included in QOL analysis
298 Completed 12 Month Visit
278 Included in NYHA analysis
273 Included in QOL analysis
270 Completed 18 Month Visit
250 Included in NYHA analysis
244 Included in QOL analysis
243 Completed 24 Month Visit
222 Included in NYHA analysis
218 Included in QOL analysis
Total: 18
9 crossovers prior to 6 Months
3 crossovers 6-12 Months
2 crossovers 12-18 Months
0 crossovers 18-24 Months
4 crossovers after 24 months
Total: 86
33 crossovers prior to 6 Months
11 crossovers 6-12 Months
5 crossovers 12-18 Months
6 crossovers 18-24 Months
31 crossovers after 24 months
BIV ¼ biventricular; CCS ¼ clinical composite score; NYHA ¼ New York Heart Association; QOL ¼ quality of life; RV ¼ right ventricular.
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2151subjects improved, 24% were unchanged, and 24%
worsened, whereas with RV subjects, 39% improved,
33% were unchanged, and 28% worsened. This was a
consistent ﬁnding at each time point and typiﬁes the
magnitude of response to biventricular pacing in heart
failure patients (7–9). The greater percentage wors-
ening observed in the RV arm was driven by heart
failure hospitalizations and crossovers due to wors-
ening heart failure. Only crossovers for worsening
heart failure were included in the clinical composite
score results; crossovers for other reasons were not.
Table 2 shows a breakdown of the components of the
clinical composite score that contributed to a ﬁnding
of worsened or improved at 6 and 12 months.NYHA FUNCTIONAL CLASSIFICATION. At randomi-
zation, 13.2% of biventricular-paced subjects and
18.4% of the RV-paced subjects (Table 1) were NYHA
functional class I and therefore could not show
improvement over time. At 12 months, the biven-
tricular arm had greater improvement in NYHA
functional class (PP ¼ 0.99), with more than 19%
improved, 61% unchanged, and more than 17%
worsened, compared with the RV arm, which had
more than 12% improved, 62% unchanged, and more
than 23% worsened (Figure 2A). The differences
between biventricular and RV pacing at the other
time points did not meet the threshold of statistical
beneﬁt. Because subjects who crossed over from RV
TABLE 1 Demographics
CRT-P
(n ¼ 484)
CRT-D
(n ¼ 207)
All Randomized Subjects
(n ¼ 691)
Biventricular
(n ¼ 243)
RV
(n ¼ 241)
Biventricular
(n ¼ 106)
RV
(n ¼ 101)
Biventricular
(n ¼ 349)
RV
(n ¼ 342)
Male 181 (74.5) 168 (69.7) 87 (82.1) 81 (80.2) 268 (76.8) 249 (72.8)
Age, yrs 74.4  10.2 73.8  10.8 72  9.3 71  10 73.7  10 73.0  10.6
Heart rate, beats/min 68.7  23.4 68.7  23.9 68.2  16.9 69.1  17.4 68.5  21.6 68.8  22.2
QRS duration, ms 125.4  32.8 124.5  31.1 122.5  30.1 119.3  30.2 124.6  32 123.0  30.8
LVEF, % 43.4  6.5 42.5  6.6 33.0  7.8 32.9  8.0 40.3  8.4 39.6  8.3
NYHA functional class
I 35 (14.4) 47 (19.5) 11 (10.4) 16 (15.8) 46 (13.2) 63 (18.4)
II 141 (58.0) 126 (52.3) 67 (63.2) 58 (57.4) 208 (59.6) 184 (53.8)
III 66 (27.2) 68 (28.2) 28 (26.4) 27 (26.7) 94 (26.9) 95 (27.8)
Cardiomyopathy
Ischemic 94 (38.7) 91 (37.8) 67 (63.2) 59 (58.4) 161 (46.1) 150 (43.9)
Nonischemic 47 (19.3) 65 (27.0) 26 (24.5) 25 (24.8) 73 (20.9) 90 (26.3)
Unknown 2 (1.0) 6 (3.1) 2 (1.9) 3 (3.0) 4 (1.1) 9 (2.6)
Other 9 (3.7) 6 (2.5) 2 (1.9) 2 (2.0) 11 (3.2) 8 (2.3)
Atrial ﬁbrillation 136 (56.0) 133 (55.2) 44 (41.5) 52 (51.5) 180 (51.6) 185 (54.1)
Atrioventricular block
1st degree 39 (16.0) 35 (14.5) 29 (27.4) 31 (30.7) 68 (19.5) 66 (19.3)
2nd degree 84 (34.6) 70 (29.0) 35 (33.0) 38 (37.6) 119 (34.1) 108 (31.6)
3rd degree 120 (49.4) 135 (56.0) 42 (39.6) 32 (31.7) 162 (46.4) 167 (48.8)
Left bundle branch block 86 (35.4) 75 (31.1) 37 (34.9) 27 (26.7) 123 (35.2) 102 (29.8)
Values are n (%) or mean  SD.
CRT-D ¼ cardiac resynchronization therapy deﬁbrillator; CRT-P ¼ cardiac resynchronization therapy pacemaker; LVEF ¼ left ventricular ejection fraction; NYHA ¼ New York
Heart Association; RV ¼ right ventricular.
TABLE 2 Clinical Composite Score
6-Month Visit 12-Month Visit 18-Month Visit 24-Month Visit
Biventricular
(n ¼ 349)
RV
(n ¼ 342)
Biventricular
(n ¼ 345)
RV
(n ¼ 341)
Biventricular
(n ¼ 325)
RV
(n ¼ 323)
Biventricular
(n ¼ 308)
RV
(n ¼ 314)
Worsened 82 (23.5) 96 (28.1) 103 (29.9) 146 (42.8) 120 (36.9) 150 (46.4) 120 (39.0) 161 (51.3)
Death 10 (2.9) 16 (4.7) 23 (6.7) 23 (6.7) 30 (9.2) 30 (9.3) 38 (12.3) 39 (12.4)
HF hospitalization 18 (5.2) 33 (9.6) 28 (8.1) 48 (14.1) 35 (10.8) 53 (16.4) 37 (12.0) 54 (17.2)
Therapy discontinuation/crossover
due to worsening HF
0 (0) 12 (3.5) 0 (0) 13 (3.8) 0 (0) 13 (4.0) 0 (0) 16 (5.1)
Therapy discontinuation at exit
with worsening HF
0 (0) 0 (0) 0 (0) 1 (0.3) 0 (0) 1 (0.3) 0 (0) 1 (0.3)
Worsened NYHA functional class 50 (14.3) 33 (9.6) 50 (14.5) 58 (17.0) 51 (15.7) 50 (15.5) 42 (13.6) 48 (15.3)
Moderately/markedly worse global
assessment
4 (1.1) 2 (0.1) 2 (0.1) 3 (0.8) 4 (1.2) 3 (0.9) 3 (1.0) 3 (0.9)
Improved 184 (52.7) 133 (38.9) 160 (46.4) 117 (34.3) 137 (42.2) 103 (31.9) 118 (38.3) 94 (29.9)
Moderately or markedly improved on
subject global assessment and
improved NYHA functional class
37 (10.6) 26 (7.6) 39 (11.3) 23 (6.7) 32 (9.8) 22 (6.8) 24 (7.8) 13 (4.1)
Moderately or markedly improved on
subject global assessment only
126 (36.1) 91 (26.6) 100 (29.0) 85 (24.9) 87 (26.8) 66 (20.4) 80 (26.0) 63 (20.1)
Improved NYHA functional class only 21 (6.0) 16 (4.7) 21 (6.1) 9 (2.6) 18 (5.5) 15 (4.6) 14 (4.5) 18 (5.7)
Unchanged 83 (23.8) 113 (33.0) 82 (23.8) 78 (22.9) 68 (20.9) 70 (21.7) 70 (22.7) 59 (18.8)
Posterior probability 0.998 0.999 0.998 0.998
Values are n (%) unless otherwise indicated. Subjects who did not complete follow-up visits due to study closure were removed from the analysis at the corresponding endpoint
if they did not meet a “worsened” classiﬁcation.
HF ¼ heart failure; other abbreviations as in Table 1.
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FIGURE 2 Change in NYHA Functional Classiﬁcation Over Time
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PP=0.591 PP=0.986 PP=0.726 PP=0.701
PP=0.691 PP=0.998 PP=0.945 PP=0.952
17% 15%
64% 70%
17% 14%
19% 12%
61% 62%
17% 23%
18% 18%
59% 56%
21% 22%
16% 16%
62% 57%
19% 24%
17% 14%
65% 70%
16% 14% 16% 25%
63% 62%
19% 11% 17% 16% 16% 14%
61% 57%
19% 23%
64% 56%
17% 25%
Improved by 2 Classes
Improved by 1 Class
Unchanged
Worsened by 1 Class
Worsened by 2 Classes
A
B 
The percentage of subjects in each arm is partitioned according to how their NYHA
functional classiﬁcation changed relative to randomization. A posterior probability
(PP) $0.95 was the pre-speciﬁed threshold for an important difference between groups.
(A) Intent-to-treat analysis. (B) Accounting for crossovers. The number of patients
analyzed in each group is shown at the bottom. Abbreviations as in Figure 1.
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2153to biventricular pacing due to worsening heart failure
may beneﬁt from biventricular pacing, a sensitivity
analysis was done substituting NYHA functional
classiﬁcation values at the time of crossover or the
most recent value before crossover for post-crossover
scores. Bayesian analysis using LOCF also showed
superior improvement in NYHA functional class at 18
and 24 months among biventricular-paced subjects
(PP $0.95) (Figure 2B), suggesting that in addition to
having fewer subjects at later time points due to the
trial design, the results at 18 and 24 months may have
been inﬂuenced by the imbalance in crossovers be-
tween the 2 arms.
QUALITY OF LIFE. QOL was superior (PP $0.95) for
biventricular-paced compared with RV-paced pa-
tients through 12 months of follow-up. The average
QOL scores at randomization among subjects ran-
domized to the biventricular and RV arms were 26.8
and 24.9, respectively. Subjects in the biventricular
arm improved from randomization by an average of 5
units at 6 months and 3.9 units at 12 months,
compared with a negligible improvement in the RV
arm over a similar time frame (Central Illustration). At
later time points, average improvements of 2.3 to 2.6
units were observed in the biventricular arm, but the
differences were not signiﬁcant compared with the
RV arm. However, when the analysis was redone
mitigating the effect of crossovers (similar LOCF
analysis as with NYHA functional class), the observed
average improvements in the RV arm at 18 and 24
months observed in the main analysis did not occur.
Superiority of biventricular pacing was demonstrated
at 6, 12, and 18 months (Central Illustration), whereas
at 24 months, the difference had high PP (PP ¼ 0.93).
DISCUSSION
This analysis of the BLOCK HF trial demonstrates that
important clinical outcomes are improved with
biventricular pacing compared with RV pacing in pa-
tients with atrioventricular block, left ventricular
dysfunction, and NYHA functional class I to III
symptoms.
CLINICAL OUTCOMES WITH CRT IN ADVANCED
HEART FAILURE. A number of prior studies of CRT
for the treatment of advanced heart failure with
prolonged QRS duration have demonstrated favorable
changes in QOL, exercise capacity, and NYHA func-
tional class with biventricular pacing. The MIRACLE
(Multicenter InSync Randomized Clinical Evaluation)
study found that, in patients with NYHA func-
tional class III to IV symptoms, LVEF #35%, and
QRS duration >130 ms, CRT compared with a control
CENTRAL ILLUSTRATION Clinical Outcomes With BIV Versus RV Pacing: Change in QOL Over Time
Curtis, A.B. et al. J Am Coll Cardiol. 2016;67(18):2148–57.
The observed mean improvement in quality of life (QOL) relative to randomization for each arm at each time point. A posterior probability
(PP) $0.95 was the pre-speciﬁed threshold for an important difference between groups. (A) Intent-to-treat analysis. (B) Accounting for
crossovers The number of patients analyzed in each group is shown at the bottom. BIV ¼ biventricular; RV ¼ right ventricular.
Curtis et al. J A C C V O L . 6 7 , N O . 1 8 , 2 0 1 6
Clinical Outcomes in the BLOCK HF Study M A Y 1 0 , 2 0 1 6 : 2 1 4 8 – 5 7
2154
J A C C V O L . 6 7 , N O . 1 8 , 2 0 1 6 Curtis et al.
M A Y 1 0 , 2 0 1 6 : 2 1 4 8 – 5 7 Clinical Outcomes in the BLOCK HF Study
2155group was associated with improvement in 6-min
walk time (þ39 vs. þ10 m, p ¼ 0.005), functional
class (p < 0.001), and QOL using the Minnesota Living
With Heart Failure Questionnaire (18.0 vs. 9.0
points, p ¼ 0.001) (7). Sixty-eight percent (68%) of the
CRT patients had improvement of 1 or more NYHA
functional classes, 30% were unchanged, and only
2% were worse. The clinical composite score also
signiﬁcantly improved with biventricular pacing. In
the COMPANION (Comparison of Medical Therapy,
Pacing, and Deﬁbrillation in Heart Failure) trial,
the ﬁndings of an exercise substudy were that 6-min
walk distance, NYHA functional class, and QOL
improved at 6 months compared with the group on
optimal medical therapy (10). The CARE-HF (Cardiac
Resynchronization–Heart Failure) study had
long-term follow-up of QOL in patients with
moderate-to-severe heart failure who received CRT
and found that, with a median follow-up of 29.6
months, QOL was signiﬁcantly improved at every
time point (p < 0.0001) compared with optimal
medical therapy (mean difference in disease-speciﬁc
QOL score of 10.7, mostly due to improved physical
functioning) (11). Of note, in all these trials, the pa-
tients studied had more advanced heart failure,
which is associated with worse QOL at baseline and
thus with a correspondingly greater room for
improvement with effective therapy.
CLINICAL OUTCOMES WITH CRT IN MILD HEART
FAILURE. Several more recent studies have investi-
gated the use of CRT in less advanced heart failure. In
the REVERSE (Remodeling in Systolic Left Ventricular
Dysfunction) study, patients with NYHA functional
class I to II symptoms, QRS $120 ms, and an
LVEF #40% received CRT devices (CRT-P or CRT-D)
and were randomized to CRT-ON or CRT-OFF (9).
The primary endpoint was the clinical composite
score at 12 months, which worsened in 16% of the
patients with CRT-ON versus 21% in the CRT-OFF
group (p ¼ 0.10). Although there was not a signiﬁ-
cant difference in clinical composite score between
the 2 groups at 12 months, the European cohort of the
study was followed out to 2 years, and in this group,
19% of CRT-ON patients worsened versus 34% in the
CRT-OFF group (p ¼ 0.01). There was also favorable
left ventricular reverse remodeling and a delay in
time to death or ﬁrst heart failure hospitalization (12).
The MADIT-CRT trial (Multicenter Automatic Deﬁ-
brillator Implantation Trial with Cardiac Resynchro-
nization Therapy) randomized patients with an
LVEF #30%, QRS $130 ms, and NYHA functional class
I to II symptoms to a CRT-D or an implantable car-
dioverter deﬁbrillator alone (13). The CRT-D grouphad a signiﬁcant reduction in the primary endpoint,
death or nonfatal heart failure event. The QOL sub-
study used the Kansas City Cardiomyopathy Ques-
tionnaire. During a mean follow-up of 2.4 years, the
CRT-D group had a greater improvement in all mea-
sures (p < 0.05), although the beneﬁt was limited to
those with left bundle branch block at baseline
(p < 0.01 vs. p ¼ not signiﬁcant in those without left
bundle branch block) (14).
The RAFT (Resynchronization-Deﬁbrillation for
Ambulatory Heart Failure) trial randomized patients
with NYHA functional class II to III heart failure, QRS
>120 ms, and an LVEF <30% to CRT-D or implantable
cardioverter deﬁbrillator alone (15). The primary
outcome, death or hospitalization for heart failure,
was signiﬁcantly reduced in the CRT-D arm. In addi-
tion, patients treated with CRT-D showed a trend for
a greater improvement in Minnesota Living With
Heart Failure score between baseline and 6 months
(CRT-D 41  21 to 31  21; implantable cardioverter
deﬁbrillator 33  20 to 28  20; p ¼ 0.057) (16).
The MIRACLE ICD II (Multicenter InSync ICD Ran-
domized Clinical Evaluation II) trial randomized pa-
tients with NYHA functional class II symptoms,
LVEF #35%, and a QRS $130 ms to CRT-D or
implantable cardioverter deﬁbrillator therapy alone
(8). The primary outcome measure, change in peak
VO2 at 6 months, was not signiﬁcantly different be-
tween the 2 arms of the study. Among the pre-
speciﬁed secondary outcome measures, LVEF
improved, ventricular volumes decreased, and there
were signiﬁcant improvements in NYHA functional
class and clinical composite score in patients ran-
domized to CRT-D therapy. On the other hand, there
was no difference in 6-min walk distance or QOL
score.
In a meta-analysis of CRT trials in less symptomatic
heart failure patients that included these aforemen-
tioned trials, the overall conclusion was that CRT
reduced mortality and heart failure hospitalizations,
but it did not have a signiﬁcant impact on functional
outcomes or QOL (17). In a more recent meta-analysis,
Chen et al. (18) found that QOL improved with CRT,
but only in NYHA functional class III to IV patients,
not those with milder heart failure. Given the milder
degrees of heart failure in these studies, the likeli-
hood is that longer durations of follow-up would be
necessary to demonstrate better clinical outcomes
compared to those with more advanced heart failure.
CLINICAL OUTCOMES IN THE BLOCK HF STUDY. In
the context of the aforementioned clinical trials, it
might have been expected that it would be chal-
lenging to demonstrate improvement in endpoints
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: In patients with atrioven-
tricular block and mild-to-moderate heart failure,
biventricular pacing is associated with improvement in
the composite outcome of death, heart failure-related
urgent care, and adverse ventricular remodeling
compared with right ventricular pacing, and these
advantages translate into better functional capacity
and quality of life.
TRANSLATIONAL OUTLOOK: Future research
should examine whether patients with less advanced
atrioventricular block gain comparable beneﬁt from
biventricular pacing or strategies that minimize ven-
tricular pacing.
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study, given the relatively milder symptoms in these
patients at baseline. Of the total study population,
73% were NYHA functional class I or II. Despite this,
we were able to demonstrate improvement in clinical
composite score at all time points through 24 months,
improvement in NYHA functional class at 12 months,
and QOL through 12 months of follow-up. It should
also be noted that the relatively high number of
crossovers in the study would tend to dilute the dif-
ferences between the biventricular and RV pacing
groups, yet we still found signiﬁcant differences in
favor of biventricular pacing.
One other key factor is that BLOCK HF was a study
of different modalities of pacing in patients with left
ventricular dysfunction who develop a need for a
high percentage of pacing for atrioventricular block.
Thus, biventricular pacing in these patients may be
preventing future dyssynchrony and heart failure as
much as treating currently existing dyssynchrony. In
that regard, our ﬁndings could reﬂect a mix of
improvement in clinical outcomes as well as preven-
tion of deterioration in clinical condition.
CROSSOVERS. Most crossovers in the RV pacing arm
occurred because of worsening heart failure. In-
vestigators were strongly encouraged to keep subjects
in their randomized group until they had reached at
least 1 of the components of the composite primary
endpoint. Given the main conclusion of this study,
that biventricular pacing is superior to RV pacing in
patients with atrioventricular block and left ventric-
ular dysfunction, then loss of biventricular pacing in
the biventricular arm or conversion to biventricular
pacing in the RV pacing arm would tend to reduce the
differences between the 2 study groups. Despite this,
we have shown signiﬁcant differences between treat-
ment groups in important clinical outcomes.
STUDY LIMITATIONS. The primary limitation for the
assessment of NYHA functional class, QOL, and clin-
ical composite score was missing data due to either
missed visits or study closure. Because the trial was
designed to follow subjects through at least 12
months, some subjects did not have the opportunity
to complete their 18- or 24-month visits, resulting in
reduced sample sizes for assessments at these timepoints. Additionally, between 5% and 7% of expected
visits at each time point were missed. There was an
imbalance in crossovers between the arms, and
sensitivity analyses showed that results at later time
points may have been affected by discontinuation of
randomized therapy.
CONCLUSIONS
We have shown that clinical outcomes, QOL, and
heart failure status are improved with biventricular
pacing compared to RV pacing in the BLOCK HF
study. These results demonstrate that, in addition to
the main ﬁndings of the trial (a reduction in the
composite endpoint of death, heart failure–related
urgent care, and adverse ventricular remodeling with
biventricular pacing), important clinical outcomes are
improved as well. The ﬁndings with biventricular
pacing may reﬂect prevention of future dyssynchrony
and heart failure as well as treatment of currently
existing dyssynchrony.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Anne B. Curtis, University at Buffalo, 100 High Street,
D2-76, Buffalo, New York 14203. E-mail: abcurtis@
buffalo.edu.RE F E RENCE S1. Lamas GA, Lee KL, Sweeney MO, et al. Ven-
tricular pacing or dual-chamber pacing for sinus-
node dysfunction. N Engl J Med 2002;346:
1854–62.
2. Wilkoff BL, Cook JR, Epstein AE, et al.
Dual-chamber pacing or ventricular backuppacing in patients with an implantable deﬁ-
brillator: the Dual Chamber and VVI Implant-
able Deﬁbrillator (DAVID) trial. JAMA 2002;
288:3115–23.
3. Gillis AM, Purerfellner H, Israel CW, et al.
Reducing unnecessary right ventricular pacingwith the managed ventricular pacing mode in pa-
tients with sinus node disease and AV block. Pac-
ing Clin Electrophysiol 2006;29:697–705.
4. Curtis AB, Adamson PB, Chung E, et al. Biven-
tricular Versus Right Ventricular Pacing in Patients
With AV Block (BLOCK HF): clinical study design
J A C C V O L . 6 7 , N O . 1 8 , 2 0 1 6 Curtis et al.
M A Y 1 0 , 2 0 1 6 : 2 1 4 8 – 5 7 Clinical Outcomes in the BLOCK HF Study
2157and rationale. J Cardiovasc Electrophysiol 2007;
18:965–71.
5. Curtis AB, Worley SJ, Adamson PB, et al.
Biventricular pacing for atrioventricular block and
systolic dysfunction. N Engl J Med 2013;368:
1585–93.
6. Packer M. Proposal for a new clinical end point
to evaluate the efﬁcacy of drugs and devices in the
treatment of chronic heart failure. J Card Fail
2001;7:176–82.
7. Abraham WT, Fisher WG, Smith AL, et al. Car-
diac resynchronization in chronic heart failure.
N Engl J Med 2002;346:1845–53.
8. Abraham WT, Young JB, Leon AR, et al. Effects
of cardiac resynchronization on disease progression
in patients with left ventricular systolic dysfunc-
tion, an indication for an implantable cardioverter-
deﬁbrillator, and mildly symptomatic chronic heart
failure. Circulation 2004;110:2864–8.
9. Linde C, Abraham WT, Gold MR, et al. Ran-
domized trial of cardiac resynchronization in
mildly symptomatic heart failure patients and in
asymptomatic patients with left ventricular
dysfunction and previous heart failure symptoms.
J Am Coll Cardiol 2008;52:1834–43.10. De Marco T. Impact of cardiac resynchroniza-
tion therapy on exercise performance, functional
capacity, and quality of life in systolic heart failure
with QRS prolongation: COMPANION trial sub-
study. J Card Fail 2008;14:9–18.
11. Cleland JGF, Calvert MJ, Verboven Y,
Freemantle N. Effects of cardiac resynchronization
therapy on long-term quality of life: an analysis
from the CArdiac Resynchronisation-Heart Failure
(CARE-HF) study. Am Heart J 2009;157:457–66.
12. Daubert C, Gold MR, Abraham WT, et al. Pre-
vention of disease progression by cardiac
resynchronization therapy in patients with
asymptomatic or mildly symptomatic left ventric-
ular dysfunction: insights from the European
cohort of the REVERSE (Resynchronization Re-
verses Remodeling in Systolic Left Ventricular
Dysfunction) trial. J Am Coll Cardiol 2009;54:
1837–46.
13. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-
resynchronization therapy for the prevention of
heart-failure events. N Engl J Med 2009;361:
1329–38.
14. Veazie PJ, Noyes K, Li Q, et al. Cardiac
resynchronization and quality of life in patientswith minimally symptomatic heart failure. J Am
Coll Cardiol 2012;60:1940–4.
15. Tang ASL, Wells GA, Talajic M, et al. Cardiac-
resynchronization therapy for mild-to-moderate
heart failure. N Engl J Med 2010;363:2385–95.
16. Healey JS, Hohnloser SH, Exner DV, et al.
Cardiac resynchronization therapy in patients with
permanent atrial ﬁbrillation: results from the
Resynchronization for Ambulatory Heart Failure
Trial (RAFT). Circ Heart Fail 2012;5:566–70.
17. Al-Majed NS, McAlister FA, Bakal JA,
Ezekowitz JA. Meta-analysis: cardiac resynchroni-
zation therapy for patients with less symptomatic
heart failure. Ann Intern Med 2011;154:401–12.
18. Chen S, Yin Y, Krucoff MW. Effect of cardiac
resynchronization therapy and implantable car-
dioverter deﬁbrillator on quality of life in patients
with heart failure: a meta-analysis. Europace 2012;
14:1602–7.KEY WORDS atrioventricular block,
biventricular pacing, cardiac
resynchronization therapy, heart failure,
quality of life
